Therapy-naïve PDAC tumor specimens (resections and biopsies; Table S2) of 10 patients per group from the PREDICT trial were evaluated representing either short (S-TTF2) or long (L-TTF2) second-line treatment durations, i.e., the bottom and top 40th-percentiles of TTF2 values, respectively (Fig. S1A, Fig. 1A-B). Here, TTF2 is linked to neoplasm.